Literature DB >> 3901986

Local cyclosporine therapy for experimental autoimmune uveitis in rats.

R B Nussenblatt, W J Dinning, L S Fujikawa, C C Chan, A G Palestine.   

Abstract

The use of locally applied cyclosporine was investigated in the retinal S-antigen-induced experimental autoimmune uveitis (EAU) model in Lewis rats. A 2% cyclosporine solution applied topically four times a day for 14 days effectively prevented the expression of EAU. This treatment, however, produced circulating cyclosporine levels in the therapeutic range. Lower concentrations of cyclosporine applied topically did not produce therapeutic levels and were not capable of reliably preventing disease. Intraocular levels of cyclosporine, measured by radioimmunoassay, were extremely low and outside the accepted therapeutic range. Intravitreal cyclosporine therapy appeared to protect eyes from EAU, without producing significant circulating cyclosporine levels. These findings show that, in its present form, cyclosporine in oil is not an efficacious topical therapy. Therefore, a local cyclosporine preparation with enhanced penetration into the globe may be a practical approach to therapy in the future.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3901986     DOI: 10.1001/archopht.1985.01050100135035

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  16 in total

Review 1.  New developments in sustained release drug delivery for the treatment of intraocular disease.

Authors:  G Velez; S M Whitcup
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

2.  Liposome-bound cyclosporine: aqueous and vitreous level after subconjunctival injection.

Authors:  A A Alghadyan; G A Peyman; B Khoobehi; S Milner; K R Liu
Journal:  Int Ophthalmol       Date:  1988       Impact factor: 2.031

Review 3.  A look at autoimmunity and inflammation in the eye.

Authors:  Rachel R Caspi
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

4.  Prevention of experimental corneal allograft rejection in rabbits using cyclosporin-collagen shields.

Authors:  K Mahlberg; R J Uusitalo; B Gebhardt; H E Kaufman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

5.  Intravitreal implantation of the biodegradable cyclosporin A drug delivery system for experimental chronic uveitis.

Authors:  Xiaoguang Dong; Weiyun Shi; Gongqiang Yuan; Lixin Xie; Shenguo Wang; Ping Lin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-09-15       Impact factor: 3.117

6.  Influence of topical cyclosporine A and dissolvent on corneal epithelium permeability of fluorescein.

Authors:  J M Benítez del Castillo; A Castillo; N Toledano; S Durán; C del Aguila; M Otero; J García-Sanchez
Journal:  Doc Ophthalmol       Date:  1995       Impact factor: 2.379

7.  In vivo release and retinal toxicity of cyclosporine-loaded intravitreal device.

Authors:  Felipe Piacentini Paes de Almeida; Juliana Barbosa Saliba; Jefferson Augusto Santana Ribeiro; Rubens Camargo Siqueira; Sílvia L Fialho; Armando Silva-Cunha; Rodrigo Jorge; Andre Messias
Journal:  Doc Ophthalmol       Date:  2015-11-17       Impact factor: 2.379

Review 8.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

9.  Cyclosporine effects on optic nerve and retinal vasculitis in Behçet's disease.

Authors:  P S Chavis; S R Antonios; K F Tabbara
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

10.  Application of sustained delivery microsphere of cyclosporine A for preventing posterior capsular opacification in rabbits.

Authors:  Cheng Pei; Yi Xu; Jean Xin Jiang; Li-Jun Cui; Li Li; Li Qin
Journal:  Int J Ophthalmol       Date:  2013-02-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.